Echo Therapeutics, Inc. - FORM 8-K - December 14, 2016

Attached files

file filename
EX-99.1 - PRESS RELEASE, DATED DECEMBER 12, 2016. - Echo Therapeutics, Inc.ex99-1.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): December 12, 2016
 
Echo Therapeutics, Inc.
 (Exact name of Company as specified in its charter)
 
Delaware
 
001-35218
 
41-1649949
(State or other jurisdiction
of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
 
99 Wood Avenue South, Suite 302
Iselin, NJ
 
 
 
 
08830
(Address of principal executive offices)
 
 
 
(Zip Code)
 
Company’s telephone number, including area code: (732) 201-4194
 
 (Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
Item 8.01.                                  Other Events.
 
On December 12, 2016, Echo Therapeutics, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1.
 
Item 9.01.                                  Financial Statements and Exhibits.
 
(d)             Exhibits.
 
99.1            
Press Release, dated December 12, 2016.
 
 
 
 
 
 
SIGNATURES
 
              Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                                                                                    
 
ECHO THERAPEUTICS, INC.
 
 
Dated: December 14, 2016
By: /s/ Alan W. Schoenbart
 
Alan W. Schoenbart
 
 
Interim Chief Executive Officer
 
 
 
 
 
 
 
 
 
 
 
 
 

Echo Therapeutics, Inc. Reports